VTAK Stock Summary and Trading Ideas (Catheter Precision | AMEX:VTAK)

Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.

Catheter Precision trades on the AMEX stock market under the symbol VTAK.

As of August 21, 2026, VTAK stock price was flat at $0.21 with 355,466 million shares trading.

VTAK has a beta of 2.94, meaning it tends to be more sensitive to market movements. VTAK has a correlation of 0.01 to the broad based SPY ETF.

VTAK has a market cap of $755,462.00. This is considered a Sub-Micro Cap stock.

In the last 3 years, VTAK traded as high as $8.40 and as low as $.15.

VTAK has underperformed the market in the last year with a price return of -93.0% while the SPY ETF gained +21.7%. VTAK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -73.7% and -25.5%, respectively, while the SPY returned +3.4% and -1.0%, respectively.

VTAK support price is $.19 and resistance is $.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTAK shares will trade within this expected range on the day.